QLF4113
/ Qilu Pharma, QLSF Biotherapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 10, 2026
QLF4113 in Participants With Metastatic Prostate Cancer
(clinicaltrials.gov)
- P1 | N=140 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1